VanEck Biotech ETF
BBH
111 hedge funds and large institutions have $158M invested in VanEck Biotech ETF in 2021 Q2 according to their latest regulatory filings, with 13 funds opening new positions, 26 increasing their positions, 27 reducing their positions, and 7 closing their positions.
463% more call options, than puts
Call options by funds: $2.72M | Put options by funds: $484K
86% more first-time investments, than exits
New positions opened: 13 | Existing positions closed: 7
16% more capital invested
Capital invested by funds: $136M → $158M (+$21.7M)
6% more funds holding
Funds holding: 105 → 111 (+6)
0.59% less ownership
Funds ownership: 28.06% → 27.47% (-0.59%)
4% less repeat investments, than reductions
Existing positions increased: 26 | Existing positions reduced: 27
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$1.79M |
| 2 |
FTUS
Flow Traders U.S.
New York
|
+$1.54M |
| 3 |
WANY
Wealthspire Advisors (New York)
New York
|
+$1.37M |
| 4 |
PP
Prudential plc
London, England,
United Kingdom
|
+$931K |
| 5 |
Millennium Management
New York
|
+$589K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FP
Financial Perspectives
Minneapolis,
Minnesota
|
-$2.86M |
| 2 |
KAS
Kestra Advisory Services
Austin,
Texas
|
-$2.1M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$2.05M |
| 4 |
BRC
BHF RG Capital
Scottsdale,
Arizona
|
-$1.96M |
| 5 |
Goldman Sachs
New York
|
-$527K |
BBH Hedge Fund Activity: Q2 2021 in Review
111 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in VanEck Biotech ETF (BBH) for Q2 2021, worth a combined $158M — up 16% from $136M a quarter earlier.
Buyers outnumbered sellers: 13 funds opened new BBH positions and 7 closed out — a net gain of 6 holders — while 26 added to existing stakes and 27 trimmed.
The largest buyer was Susquehanna International Group, adding an estimated $1.79M. The largest seller was Financial Perspectives, cutting an estimated $2.86M.
- 111 institutional investors held VanEck Biotech ETF (BBH) as of Q2 2021, up from 105 in Q1 2021.
- Funds reported $158M of VanEck Biotech ETF stock for Q2 2021, up 16% quarter-over-quarter.
- 13 funds opened new VanEck Biotech ETF positions in Q2 2021 and 7 closed out, a net change of +6 holders.
- The largest VanEck Biotech ETF buyer in Q2 2021 was Susquehanna International Group, an estimated $1.79M added.
- The largest VanEck Biotech ETF seller in Q2 2021 was Financial Perspectives, an estimated $2.86M sold.
Based on aggregated 13F filings for Q2 2021.